Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects

doi:10.3748/wjg.v20.i24.7830

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 24

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15610)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

1015

WORD

333

HTML

11645

Figures (1-1)

230

Tables (1-6)

395

Sum=13618

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1118

Download

874

Sum=1992

Jun 28, 2014 (publication date) through May 10, 2024

Times Cited of This Article

Times Cited (72)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 28, 2014; 20(24): 7830-7848
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7830

Table 6 Trials using epigenetic agents in pancreatic cancer

Compound	Combination	Phase	Endpoint	ClincialTrials.gov	Treatment
DNMT inhibitors
Azacitidine	+ Gemcitabine	I	MTD	NCT01167816
Azacitidine		II	PFS	NCT01845805	2
Decitabine		Various stages of development for solid tumors			3
Zebularine		Preclinical
HDAC inhibitors
Vorinostat	+ Marizomib	I	MTD	NCT00667082[234]
Vorinostat	+ Radiation	I/II	MTD, PFS	NCT00948688
Vorinostat	+ 5-FU	I/II	MTD, PFS	NCT00948688
Vorinostat	+ Radiation	I	MTD	NCT00983268
Vorinostat	+ Capecitabine	I	MTD	NCT00983268
Vorinostat	+ Radiation	I/II	MTD	NCT00831493
Belinostat		Various stages of development for solid tumors
Entinostat		I	MTD	NCT00020579[235]
Entinostat	13-cis retinoic acid	I	MTD
Panobinostat	+ Bortezomib	II	PFS	NCT01056601[236]	1
HAT inhibitors
Curcumin		II	Survival	NCT00094445[147]	1
Curcumin	+ Gemcitabine	II	TTP	NCT00192842	1
Curcumin	+ Gemcitabine	III		NCT00486460	1
Curcumin	+ Celecoxib	III		NCT00486460	1
Curcumin		I	MTD	-[237]
Curcumin	+ Gemcitabine	I	MTD	-[238]
Curcumin	+ Gemcitabine	I/II	MTD	-[239]

1: Palliative; 2: Postoperative adjuvant; 3: Both. MTD: Maximum tolerated dose; PFS: Progression-free survival; HDAC: Histone deacetylase; HAT: Histone acetyltransferase.

Citation: Neureiter D, Jäger T, Ocker M, Kiesslich T. Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects. World J Gastroenterol 2014; 20(24): 7830-7848
URL: https://www.wjgnet.com/1007-9327/full/v20/i24/7830.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i24.7830